BME100 s2015:Group14 12pmL2

From OpenWetWare
Jump to navigationJump to search
BME 100 Spring 2015 Home
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help


Name: Nathan Francois
Name: Lexi Bounds
Name: Dakota Graham
Name: Thor Kissman
Name: Justin Mieth


Descriptive Statistics

Experiment 1 - Rats
For the rat experiment, the average inflammation was 10.516 pg/ml for 0mg of LPS and 11.112 pg/ml for 10mg. The standard deviation of the results was 2.2255516 pg/ml for 0mg, and 7.40289 pg/ml for 10mg, and the standard error was 0.9952969 for 0mg and 7.4029 for 10mg. The calculated p values for the rat subjects was 0.867403497, which is greater than the desired .05 p value. From this data, we can conclude that from the rat experiment, there is no statistical evidence that the dosage of LPS increases Inflammotin protein levels.

Experiment 2 – Human Study
The human subjects Experiment 2 had an average inflammation level of 3.834 pg/ml for 0mg of LPS, 8.932 pg/ml for 5mg, 61.622 pg/ml for 10mg, and 657.941 pg/ml for 15mg. The standard deviation of these findings was 1.52301 pg/ml for 0mg, 1.593932 pg/ml for 5mg, 30.11069 pg/ml for 10mg, and 212.943 pg/ml for 15mg, and the standard error for the human section of the experiment was 0.481618 for 0mg, 0.504045 for 5mg, 9.521837 for 10mg, and 67.33848 for 15mg. The calculated p value of the human experiment was 8.59631*10^-7 for 5 mg v. 0 mg, 9.94377*10^-6 for 10 mg v. 0 mg, 1.39436*10^-8 for 15 mg v. 0 mg, 3.01859*10^-5 for 10 mg v. 5 mg, 1.57101*10^-8 for 5 mg v. 15 mg, and 6.4824*10^-8 for 10 mg v. 15 mg. A major statistical difference in each group tested was found. The corrected p-value for this data is .008333, which is still greater than the p-values found in the ANOVA and t-tests.


Experiment 1
It cannot be concluded that Inflammotin production in rats is significantly affected by LPS dosage because the t-test does not show significance.

Experiment 2
Based on the ANOVA results and the between group t-tests, humans are significantly affected by LPS dosage, and produce increased inflammotin levels with increases in dosage.


Experiment 1 and 2
Data and graph for inflammotin analysis in humans and rats


For a study in rats, a t-test was performed to determine the significance of the data found in the experiment. With the results from the t-test, it was concluded that there was no significant difference in rats who received 0 mg of LPS and 10 mg of LPS. Inflammotin levels were not affected. For the study in humans, an ANOVA was performed and a corrected p-value was used to ensure that all results were accurate. T-tests between each group were also performed to determine the significance of different levels of LPS dosage. The results of the ANOVA and the t-tests showed that in humans, LPS dosage increases inflammotin production with increasing dosage.

Possible reasons for the inconsistency between the rat and the humans study are as follows: - There were only two test groups involved in the rat study, and dosages of inflammotin were either 0 mg or 10 mg. - Rats may not be affected by LPS. They might have a different inflammotin production mechanism which isn't enhanced by LPS. They might also not produce inflammotin.

To ensure more significant results for rats, perhaps a wider range of dosages of LPS can be used. Also, a greater number of test groups can be involved. Additionally, more study should go into seeing if rats have different mechanisms for producing inflammotin. If an animal study is not effective for a critical drug, then most manufacturers probably would not want to jump in on a human study. Animal studies are important preliminaries in testing any drug or device.